

First Quarter 2023 Results

Delivering on our purpose of using the power of leading-edge science to save and improve lives around the world



Innovative pipeline advancements



Focused execution of science-led strategy



Strong performance across key growth drivers



Strong Q1 performance reflects continued business momentum

Updated 2023 financial outlook underscores underlying strength

	Worldwide Sales	GAAP EPS	Non-GAAP EPS ¹
Q1 2023	\$14.5B	\$1.11	\$1.40
2023 Outlook	\$57.7B to \$58.9B	\$5.85 to \$5.97	\$6.88 to \$7.00

Sales

KEYTRUDA®
(pembrolizumab) Injection 100 mg

Grew ▲ to
20% **\$5.8B**

GARDASIL®
(Human Papillomavirus Quadrivalent
(Types 6, 11, 16, and 18) Vaccine, Recombinant)

Grew ▲ to
35% **\$2.0B**

MSD
Animal Health

Grew ▲ to
1% **\$1.5B**



“Inspired by our commitment to bring bold science forward to address critical unmet patient needs, we began 2023 with significant advancements across our innovative pipeline. Our first-quarter results are a reflection of the focused execution of our science-led strategy, strong performance across our key growth drivers, continued momentum commercially and operationally, and – most importantly – the collective and dedicated efforts of our colleagues around the world. I’m proud of the progress we’ve made, and we will continue to move with speed and agility to deliver value for patients and shareholders, now and well into the future.”

Rob Davis
Chairman and Chief Executive Officer, MSD

1. A reconciliation of GAAP to non-GAAP EPS can be found in the company’s earnings release.